ROCHESTER, Minn. (KTTC) -- A Mayo Clinic collaborator has received FDA approval for phase III of a 10-year clinical trial of its stem cell therapy for heart failure patients in the United States.
Cardio3 BioSciences will test the Mayo Clinic discovery of cardiopoietic stem cells designed to improve heart health.
The trial takes cells from the patient's body to be turned into tissue then instructed to fix a failure in the body. The main purpose of this trial is to help people heal from those who have suffered from a heart attack.
The trial known as Chart 1 in Europe has already been approved, and the U.S. trial Chart 2 is expected to begin at the end of 2014.
"We went through the financial crisis in the middle of it, in 2008. We had to find some more funding for doing that. And as one of my mentors used to say, there are no bumps in the roads. The bumps are the road. And we've encountered many of them and I'm sure we'll still have more to overcome," said Dr. Christian Homsy, CEO of Cardio3 BioSciences.
More than $100-million has been funded to this program. Phase III only focuses on patients with cardiovascular problems, but this study could lead to cures for other types of diseases.
All content © Copyright 2001 - 2014 WorldNow and KTTC, a Quincy station.
Persons with disabilities who need assistance with issues relating to the content of this station's public inspection file should contact Administrative Assistant Jodi Neyens at (507) 280-5104. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, at 888-835-5322 (TTY) or at email@example.com.